NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences declared a quarterly dividend on Monday, February 4th. Investors of record on Friday, March 15th will be paid a dividend of $0.63 per share on Thursday, March 28th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date is Thursday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.57. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Monday, February, 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing analysts' consensus estimates of $1.70 by $0.26. The biopharmaceutical company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business's quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.78 earnings per share. View Gilead Sciences' Earnings History.

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Gilead Sciences.

18 brokerages have issued 1-year price targets for Gilead Sciences' stock. Their predictions range from $68.00 to $95.00. On average, they expect Gilead Sciences' share price to reach $83.4375 in the next year. This suggests a possible upside of 26.9% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

Media stories about GILD stock have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gilead Sciences earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.

Gilead Sciences saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 11,548,612 shares, a decrease of 14.0% from the January 15th total of 13,429,498 shares. Based on an average trading volume of 7,327,632 shares, the short-interest ratio is currently 1.6 days. Approximately 0.9% of the shares of the company are short sold. View Gilead Sciences' Current Options Chain.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Celgene (CELG), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), Bank of America (BAC), Intel (INTC), Walt Disney (DIS), AT&T (T), NVIDIA (NVDA) and General Electric (GE).

Gilead Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.05%), Oregon Public Employees Retirement Fund (2.24%), Bank of New York Mellon Corp (2.21%), Northern Trust Corp (1.31%), Geode Capital Management LLC (1.30%) and Parnassus Investments CA (0.83%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, Canada Pension Plan Investment Board, State Treasurer State of Michigan, BB Biotech AG, First Manhattan Co., Boston Partners and Great West Life Assurance Co. Can. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, John C Martin, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

GILD stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Two Sigma Advisers LP, Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, Bank of Nova Scotia, Assenagon Asset Management S.A. and Mn Services Vermogensbeheer B.V.. View Insider Buying and Selling for Gilead Sciences.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GILD stock can currently be purchased for approximately $65.74.

Gilead Sciences has a market capitalization of $85.04 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

The official website for Gilead Sciences is http://www.gilead.com.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]